American Association for the Advancement of Science, Science Translational Medicine, 432(10), 2018
DOI: 10.1126/scitranslmed.aag0945
Full text: Unavailable
Targeting IL-6 and potentially FGF-2 overcomes resistance to anti-VEGF therapy in breast cancer.